Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- ASKA to Launch Generic Biz Unit; Takeda’s Yonezawa to Take Helm
September 4, 2013
- Otsuka Paid 20 Billion Yen to Healthcare Professionals in FY2012, 5.4 Billion Yen for Information Provisioning
September 4, 2013
- Fuji Yakuhin, Sanwa Kagaku Launch Gout and Hyperuricemia Treatments Topiloric/Uriadec
September 4, 2013
- President or Head of General Medicine OK’ed Research Grants to 2 Universities: Novartis Exec
September 3, 2013
- Astellas, MSD to Tie Up for SGLT-2 Inhibitor Ipragliflozin
September 3, 2013
- Chugai, Taisho Toyama to Offer Compliance Advantages with Once-Monthly Bonviva
September 3, 2013
- MTPC’s SGLT-2 Inhibitor Canagliflozin Now No. 1 in Prescription Share in US, Overtaking Januvia
September 3, 2013
- Astellas Paid 19.3 Billion Yen to Healthcare Professionals, 7.1 Billion Yen for Information Provisioning in FY2012
September 3, 2013
- Takeda’s OBLEAN Near-Certain to Debut as Japan’s 1st Anti-Obesity Drug in 20 Years
September 2, 2013
- Daiichi Sankyo Provided 36.6 Billion Yen to Physicians, Medical Institutions in FY2012, 22.7 Billion Yen for R&D
September 2, 2013
- US FDA Requests Additional Data for Tolvaptan for Treatment of ADPKD: Otsuka
September 2, 2013
- Orphan Drug Wholesaler S.D. Next to Swing into Black in FY2015 with Tailored Distribution Services: Pres.
August 30, 2013
- WHO Grants Prequalification to Eisai for Lymphatic Filariasis Treatment
August 30, 2013
- New Products Shake Up Market for Osteoporosis Treatments; Entry of Pralia Could Lead to Change in Market Structure
August 30, 2013
- AnGes MG’s CIN Therapeutic Vaccine Project Picked for Health Ministry’s Research Grants
August 29, 2013
- Merck Serono’s Northeast Asian Development Zeros in on 4 Cancer Types: R&D Site Head
August 29, 2013
- Eisai Launches Higher-Dose Aricept 23 mg Tablet in South Korea
August 29, 2013
- Shionogi Paid a Total of 10.2 Billion Yen to Healthcare Professionals, 1 Billion for Research Grants
August 28, 2013
- Takeda Initiates Overseas PIII Trial of Actos for Delaying the Onset of MCI Due to Alzheimer’s Disease
August 28, 2013
- Takeda to Appoint Mr Roger as CFO
August 28, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…